A global hit! MS Australia’s invisible symptom animation

MS Australia’s Mark Campbell tells us how the animation was developed and why it’s been such a success.

MS registries: putting people with MS at the heart of research

MS affects people all over the world. MS registries are one of the many advances in MS research that are bringing us closer as a global MS community and closer to ending MS.

MS Research Australia triumphs at national Charity Awards

MS Research Australia has been recognised for ‘Outstanding Achievement’ in the Australian Charity Awards 2018.

MS Australia’s Queensland chapter celebrates 60 years of service

As MS Queensland marks its 60th anniversary, MS Australia celebrates decades of achievements by all four of its state member organisations (MS Queensland, MS Limited, MS Society of South Australia and Northern Territory and MSWA, which services the state of Western Australia).

Sun exposure can alter risk and disease course in early MS 

New research shows that sun exposure over a lifetime can change the course of MS.

Research Australia presents award to developer of world’s largest MS database

Helmut Butzkueven, who led the development of MSBase with support from MS Research Australia, has received the Data Innovation Award.

2017: a pivotal year for the MSIF movement

This year marked the 50th anniversary of the MS International Federation, giving us a valuable opportunity to celebrate shared successes and renew our commitment to work together to achieve a world without MS.

New study shows cold water in the mouth can reduce heat sensitivity in MS

Cold water in the mouth can help reduce heat sensitivity, a common symptom of MS.

MS Australia publishes first report on MS Specialist Nurses in Australia

A major investigation into the critical role of MS Specialist Nurses in Australia could support MS Australia’s advocacy work to increase funding for MSSNs

European Medicines Agency recommends market authorisation for ocrelizumab (Ocrevus) in EU

The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS